Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

125.93
+1.230.99%
Post-market: 125.930.00000.00%19:30 EDT
Volume:12.66K
Turnover:1.59M
Market Cap:550.31M
PE:6.53
High:126.04
Open:125.39
Low:125.29
Close:124.70
52wk High:131.68
52wk Low:90.01
Shares:4.37M
Float Shares:4.37M
Volume Ratio:0.61
T/O Rate:0.29%
Dividend:1.06
Dividend Rate:0.84%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.65
PE(LYR):5.79

Loading ...

Texas Gov. Abbott, Seeking Re-Election, Touts Border Security, Voter ID Law

Dow Jones
·
Sep 11

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 11

Abbott Laboratories Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 11

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

Champions Oncology Q1 Revenue Rises on Research Services Business

Reuters
·
Sep 11

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
Sep 11

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
Sep 11

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Sep 11

Amgen’s New Repatha Plaque Trial: What Investors Should Watch

TIPRANKS
·
Sep 11

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Sep 11

Dow's 300-Point Drop Led by Losses in Shares of Nvidia Corp., Amgen

Dow Jones
·
Sep 10

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Reuters
·
Sep 10

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Sep 10

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10